
![]() | Read in Browser | |||||||||
![]() | ||||||||||
![]() | ||||||||||
![]() ![]() ![]() ![]() ![]() | ||||||||||
|
Bigger picture: Other frontrunners in the global immunization drive - AstraZeneca (NASDAQ:AZN) and Johnson & Johnson (NYSE:JNJ) - are yet to see the evidence to support the need for booster shots. The two take a similar approach in their COVID-19 vaccine technology, using viral vectors instead of the mRNA jabs produced by Pfizer and Moderna (NASDAQ:MRNA). "There are two dimensions to immunity - antibodies [which] decline over time, but the second, very important dimension of vaccination is the so-called T-cells. They tend to protect people against severe disease, but they also provide durability," AstraZeneca CEO Pascal Soriot declared. "With the technology we use, we have very high production of T-cells. We're hoping we can have a durable vaccine that protects for a long period of time."
While Pfizer intends to seek emergency use authorization for a third dose as soon as next month, the FDA and CDC currently feel that an additional dose is not necessary since Americans "who are fully vaccinated are protected from severe disease and death." US Surgeon General Dr. Vivek Murthy echoed the view this week, saying, "people do not need to go out and get a booster shot." Should the dose be approved by the FDA, the vaccine would either need to be amended or, if the vaccine were fully FDA approved, a third dose could be given off label.
Will it be the same formula? The July study conducted by Pfizer involved a third dose of its existing vaccine, but the drugmaker is also exploring whether to add an additional dose it has developed to target the Beta variant. Moderna is meanwhile testing three different booster strategies: a half-dose of the existing vaccine, an additional dose of a new vaccine that targets the Beta variant, and another dose that combines the two. Pfizer is expected to generate $33.5B in COVID-19 vaccine revenue in 2021 and Wall Street analysts have already priced boosters into their financial models for the company and BioNTech (NASDAQ:BNTX), which helped develop the vaccine with Pfizer.
Over in Israel: The country's health ministry this week recommended booster shots for older adults and to those with weak immune systems, becoming one of the first nations in the world to formally approve a third dose of Pfizer's vaccine. According to the ministry, a full course of the Pfizer vaccine was just 39% effective at preventing infections caused by the Delta variant, though the vaccine provided high levels of protection against hospitalization (92%) and severe illness (91%). Back in January, Israel struck a vaccines-for-data deal with Pfizer that promised to share vast troves of information from its highly digitized healthcare system in exchange for the continued flow of COVID-19 shots. (15 comments)
In Europe, at midday, London -0.9%. Paris -0.3%. Frankfurt -1%.
Futures at 6:20, Dow -0.3%. S&P -0.7%. Nasdaq -1.2%. Crude -0.3% at $73.38. Gold -0.2% at $1833. Bitcoin -4.3% at $38741.
Ten-year Treasury Yield -2 bps to 1.25%
Procter & Gamble (NYSE:PG) names COO Jon Moeller as new CEO
Nikola (NASDAQ:NKLA) tumbles after founder Trevor Milton charged with fraud.
Disney (NYSE:DIS) fires back at Scarlett Johansson's Black Widow lawsuit.
Male grooming startup Manscaped reportedly in talks to go public.
CRISPR (NASDAQ:CRSP) soars after massive earnings beat.
Pinterest (NYSE:PINS) tumbles after posting low user figures.
AI Day reveal by Musk recharges the Tesla (TSLA) bulls.
NASA scrubs Boeing (NYSE:BA) Starliner launch after Space Station mishap.
Two dividend ETFs that have generated 20% annualized returns for five years.


Want More Ideas?
Our best ideas → Stock Ideas
ETF's Investing Ideas → ETF Ideas
Dividend stocks ideas → Dividend Ideas
This email was sent to you because you signed up to receive Wall Street Breakfast.
If you do not want to receive Wall Street Breakfast emails, click here to unsubscribe.
Sent by Seeking Alpha, 52 Vanderbilt Avenue, 13th floor, New York, NY 10017
EmoticonEmoticon